Monitoring of patients treated with antihypertensive therapy for adverse drug reactions

Abstract

Many drugs, when licensed, list a requirement for monitoring during treatment. Frequently, the information is vague and the adherence of the prescriber and patient to the monitoring regimen is variable and often poor. There is a need for rational monitoring schemes that clinicians can adhere to and that protect patients.